Sign in
CompletedPhase 2

Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis

Key facts

Who runs it
Centre Hospitalier Universitaire Dijon
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
112 people enrolled
Started
7 Jun 2018
Ended
21 Aug 2024
Type of study
Interventional
Treatments tested
  • Daptomycin
Record updated
1 October 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Persons aged over 18 years
  • With Suspected pneumococcal meningitis :; clinical presentation evocative of pneumococcal meningitis : acute onset of ,meningeal signs, history of cranial trauma or fistula, knowledge of alteration of humoral immunity,, asplenia, alcoholism with/or; clearly purulent CSF with/ or,; presence of diplococcus on the Gram stain of CSF or positive pneumococcal antigen in the CSF, or polymorphonuclear cells in CSF > 100
  • Written consent or inclusion in an emergency
  • Affiliation to a social security system

Who cannot take part

  • Contraindication to dexamethasone
  • Previous exposition to daptomycin (within one year)
  • Immediate and severe hypersensitivity to β-lactam antimicrobial
  • Contraindication to cephalosporin
  • Contraindication to daptomycin
  • Women who are able to procreate without effective contraception and pregnant or breastfeeding women
  • Patients under ward of court
  • Refusal at any time after acceptation of the study from the patient or her/his legal representative

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Pneumococcal meningitis is an infection of the membrane that covers the brain. It is a serious infection which is currently treated with a combination of corticosteroids (dexamethasone) and 3rd generation cephalosporins. Nevertheless, complications associated with meningitis are relatively frequent and severe. Recent animal studies have shown that another antibiotic, daptomycin, can reduce the mortality and long-term effects of pneumococcal meningitis. Daptomycin is widely used worldwide in humans for other diseases, with few side effects.

Read full original descriptionShow less

This study aims to evaluate the effect of daptomycin on the proliferation of the bacterial infection, and therefore on inflammation. Daptomycin will be added to the currently recommended treatment with the same dosage used for other diseases.

Roughly 130 patients with suspected pneumococcal meningitis admitted to the emergency departments of hospitals throughout France will be asked to participate in this study.

The participation period will last approximately 3 months.

The group in the trial

  • PatientsTreatment being tested

    Treatment: Daptomycin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis: AddaMAP Study
Publications
Record updated
1 October 2024